Obesity Featured Articles

  1. How Digital Twins Are Reshaping Clinical R&D 9/28/2026

    Discover how digital twins are helping predict outcomes, streamline recruitment, reduce patient burden, and accelerate clinical development.

  2. Why Are We Still Talking About Compensating Research Participants? 9/28/2026

    Should we be compensating research participants? And is that even a question worth asking? Lindsay McNair, MD, and Ken Getz say yes despite recent data that doesn't point to a clear ROI.

  3. Examining The Potential Of P-tau217 To Provide Earlier Diagnosis Of Alzheimer's 9/25/2026

    P-tau217 blood tests could accelerate Alzheimer’s diagnosis. Lilly’s Nino Sireci, MD, MSc, explains the research, evidence thus far, potential clinical use, and next steps.

  4. Early‑Phase Autoimmune Drug Development 9/24/2026

    Adaptive designs and biomarker tracking help early autoimmune trials find true signals despite complex, variable disease patterns.

  5. NIH To Extend Plain Language Results Requirement To Funded Studies 9/24/2026

    New draft policy may require plain-language result summaries for clinical research participants. See what's in scope and how to prepare.

  6. Small Biotech Can Outsource The Work, But Not The Thinking 9/24/2026

    Robert Goldman explains why small biotechs can outsource clinical trial work—but never accountability. His advice on CRO oversight and responsible AI adoption shows how lean sponsors can gain efficiency without surrendering the judgment needed to spot risks and protect their programs.

  7. The 50-Page Monitoring Report And The Illusion Of Control 9/24/2026

    A massive decentralized trial showed why more monitoring doesn’t always mean more control — and how risk-based oversight can reveal what truly matters.

  8. Autoimmune Drugs For Women: What To Bring To The Clinic 9/24/2026

    Autoimmune disease is one of the most sex-skewed categories in medicine. Sex, reproductive status, and hormonal state should not be treated as background noise. 

  9. The Real Cost Of Sites Working Without An Enforceable Agreement: Why Your Site's Quality Of Earnings Is Suspect 9/23/2026

    Starting site work before an enforceable agreement may look like flexibility, but it can drain leverage, create unrecoverable costs, and raise financial reporting and GCP concerns.

  10. Defining Meaningful Anti-Inflammatory Response: What Early Human Data Tells Us 9/22/2026

    Controlled immune challenges link drug exposure to biological effects, helping refine dose selection, test mechanisms and support better decisions before patient trials.